Clearbridge Investments LLC Trims Stock Holdings in Celcuity, Inc. $CELC

Clearbridge Investments LLC lowered its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 20.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 106,931 shares of the company’s stock after selling 27,289 shares during the period. Clearbridge Investments LLC’s holdings in Celcuity were worth $10,665,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its position in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after acquiring an additional 319 shares in the last quarter. Ogorek Anthony Joseph NY ADV lifted its position in shares of Celcuity by 19.7% during the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after acquiring an additional 109 shares in the last quarter. US Bancorp DE grew its holdings in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares in the last quarter. NBC Securities Inc. purchased a new stake in shares of Celcuity in the fourth quarter worth about $99,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Celcuity in the fourth quarter worth about $144,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CELC shares. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Citizens Jmp boosted their price objective on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research note on Monday, May 4th. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Leerink Partners set a $155.00 price objective on Celcuity in a research report on Tuesday, June 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $157.00 price objective on shares of Celcuity in a research report on Friday, May 15th. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $152.09.

Insider Transactions at Celcuity

In other news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares of the company’s stock, valued at $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 37,000 shares of company stock valued at $5,111,950 over the last quarter. Company insiders own 13.33% of the company’s stock.

Celcuity Stock Performance

Celcuity stock opened at $88.24 on Thursday. The firm’s fifty day moving average price is $120.79 and its 200-day moving average price is $111.44. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The stock has a market cap of $4.30 billion, a P/E ratio of -22.63 and a beta of 0.10. Celcuity, Inc. has a fifty-two week low of $11.27 and a fifty-two week high of $151.02.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.10. On average, equities research analysts expect that Celcuity, Inc. will post -3.69 earnings per share for the current fiscal year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.